Skip to main content
Figure 3 | Clinical Epigenetics

Figure 3

From: Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia

Figure 3

Arsenic trioxide (ATO) does not enhance degradation of the Ae9a fusion protein or the cell cycle arrest induced by panobinostat but does lead to degradation of promyelocytic leukemia (PML) protein in A/E9a;Nras G12D tumor cells. (A) Immunoblotting of whole cell lysates prepared from A/E9a;Nras G12D tumor cells treated in vitro with either panobinostat (pan; 16 μM), ATO (2.5 μM) or a combination, for 24 hours using antibodies against A/E9a or acetylated histone H3 (AcH3), with β-actin serving as a loading control. (B) Immunoblotting of whole cell lysates prepared from A/E9a;Nras G12D tumor cells treated in vitro with either panobinostat (16 μM), ATO (2.5 μM) or the combination, for 24 hours using antibodies against PML with β-actin serving as a loading control. The results shown are representative of three experiments.

Back to article page